Immunotherapy in non-small cell lung cancer harbouring driver mutations
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Immunotherapy in non-small cell lung cancer harbouring driver mutations
Authors
Keywords
-
Journal
CANCER TREATMENT REVIEWS
Volume 96, Issue -, Pages 102179
Publisher
Elsevier BV
Online
2021-03-20
DOI
10.1016/j.ctrv.2021.102179
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- State-of-the-Art Strategies for Targeting RET-Dependent Cancers
- (2020) Vivek Subbiah et al. JOURNAL OF CLINICAL ONCOLOGY
- Efficacy and safety of anti-PD-1 immunotherapy in patients with advanced Non Small Cell Lung Cancer with BRAF, HER2 or MET mutation or RET-translocation. GFPC 01-2018.
- (2020) Florian Guisier et al. Journal of Thoracic Oncology
- Efficacy and safety of programmed cell-death-protein-1 and its ligand inhibitors in pretreated patients with epidermal growth-factor receptor-mutated or anaplastic lymphoma kinase-translocated lung adenocarcinoma
- (2020) Olivier Bylicki et al. MEDICINE
- KRAS as a druggable target in NSCLC: Rising like a phoenix after decades of development failures
- (2020) Alex Friedlaender et al. CANCER TREATMENT REVIEWS
- A BRAF new world
- (2020) Daniele Frisone et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- NRG1 fusion-driven tumors: biology, detection and the therapeutic role of afatinib and other ErbB-targeting agents
- (2020) J. Laskin et al. ANNALS OF ONCOLOGY
- The METeoric rise of MET in lung cancer
- (2020) Alex Friedlaender et al. CANCER
- Clinical features affecting survival in metastatic NSCLC treated with immunotherapy: A critical review of published data
- (2020) Antonio Passaro et al. CANCER TREATMENT REVIEWS
- KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors
- (2020) David S. Hong et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy of Selpercatinib in RET Fusion–Positive Non–Small-Cell Lung Cancer
- (2020) Alexander Drilon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Responsiveness to immune checkpoint inhibitors versus other systemic therapies in RET-aberrant malignancies
- (2020) Aparna Hegde et al. ESMO Open
- Understanding EGFR heterogeneity in lung cancer
- (2020) Antonio Passaro et al. ESMO Open
- Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial
- (2019) Martin Reck et al. Lancet Respiratory Medicine
- Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry
- (2019) J Mazières et al. ANNALS OF ONCOLOGY
- Detection of NRG1 Gene Fusions in Solid Tumors
- (2019) Sushma Jonna et al. CLINICAL CANCER RESEARCH
- Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
- (2019) Tony S K Mok et al. LANCET
- Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial
- (2019) Howard West et al. LANCET ONCOLOGY
- Rearranged During Transfection Fusions in Non-Small Cell Lung Cancer
- (2019) Connor O’Leary et al. Cancers
- Chemotherapy in Combination With Immune Checkpoint Inhibitors for the First-Line Treatment of Patients With Advanced Non-small Cell Lung Cancer: A Systematic Review and Literature-Based Meta-Analysis
- (2019) Alfredo Addeo et al. Frontiers in Oncology
- EGFR mutation subtypes and response to immune checkpoint blockade treatment in non-small-cell lung cancer
- (2019) K Hastings et al. ANNALS OF ONCOLOGY
- Association of TP53 mutations with response and longer survival under immune checkpoint inhibitors in advanced non-small-cell lung cancer
- (2019) Sandra Assoun et al. LUNG CANCER
- Therapeutic outcomes in non-small cell lung cancer with BRAF mutations: a single institution, retrospective cohort study
- (2019) Irena Tan et al. Translational Lung Cancer Research
- Diagnosis and Treatment of ALK Aberrations in Metastatic NSCLC
- (2019) Alex Friedlaender et al. CURRENT TREATMENT OPTIONS IN ONCOLOGY
- Immune Checkpoint Inhibitors in ROS1-Rearranged Non–Small Cell Lung Cancer: A Report of Two Cases
- (2019) Aditya Jain et al. Journal of Thoracic Oncology
- Role of the dynamic tumor microenvironment in controversies regarding immune checkpoint inhibitors for the treatment of non-small cell lung cancer (NSCLC) with EGFR mutations
- (2019) Anqi Lin et al. Molecular Cancer
- Targeted Therapy For RET-Rearranged Non-Small Cell Lung Cancer: Clinical Development And Future Directions
- (2019) Christoph Jakob Ackermann et al. OncoTargets and Therapy
- LBA78IMpower110: Interim overall survival (OS) analysis of a phase III study of atezolizumab (atezo) vs platinum-based chemotherapy (chemo) as first-line (1L) treatment (tx) in PD-L1–selected NSCLC
- (2019) D Spigel et al. ANNALS OF ONCOLOGY
- P1.03-16 Anti-Tumor Effect of Pan-RAF Inhibitor in NSCLC Cells Harboring BRAF Mutation
- (2019) S. Miyauchi et al. Journal of Thoracic Oncology
- Precision medicine in ALK rearranged NSCLC: A rapidly evolving scenario
- (2018) Alfredo Addeo et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Regulation and Function of the PD-L1 Checkpoint
- (2018) Chong Sun et al. IMMUNITY
- A Phase II Study of Pembrolizumab in EGFR-mutant, PD-L1+, Tyrosine Kinase Inhibitor (TKI) Naïve Patients with Advanced NSCLC
- (2018) A. Lisberg et al. Journal of Thoracic Oncology
- BRAF Mutant Lung Cancer: Programmed Death Ligand 1 Expression, Tumor Mutational Burden, Microsatellite Instability Status, and Response to Immune Check-Point Inhibitors
- (2018) Elizabeth Dudnik et al. Journal of Thoracic Oncology
- Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study
- (2018) Marina Chiara Garassino et al. LANCET ONCOLOGY
- Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC
- (2018) Mark A. Socinski et al. NEW ENGLAND JOURNAL OF MEDICINE
- STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS -Mutant Lung Adenocarcinoma
- (2018) Ferdinandos Skoulidis et al. Cancer Discovery
- PD-L1 Expression, Tumor Mutational Burden, and Response to Immunotherapy in Patients with MET exon 14 Altered Lung Cancers
- (2018) J K Sabari et al. ANNALS OF ONCOLOGY
- PD-L1 expression, tumor mutation burden and response to immune checkpoint blockade in patients with HER2-mutant lung cancers.
- (2018) Wei-Chu Victoria Lai et al. JOURNAL OF CLINICAL ONCOLOGY
- Response and durability of anti-PD-(L)1 therapy in never- or light-smokers with non-small cell lung cancer (NSCLC) and high PD-L1 expression.
- (2018) Justin F. Gainor et al. JOURNAL OF CLINICAL ONCOLOGY
- RET-rearranged lung cancers: Immunophenotype and response to immunotherapy.
- (2018) Joshua K. Sabari et al. JOURNAL OF CLINICAL ONCOLOGY
- Common driver mutations and smoking history affect tumor mutation burden in lung adenocarcinoma
- (2018) Masayuki Nagahashi et al. JOURNAL OF SURGICAL RESEARCH
- COSMIC: the Catalogue Of Somatic Mutations In Cancer
- (2018) John G Tate et al. NUCLEIC ACIDS RESEARCH
- PD-L1 expression in ROS1 -rearranged non-small cell lung cancer: A study using simultaneous genotypic screening of EGFR , ALK , and ROS1
- (2018) Jongmin Lee et al. Thoracic Cancer
- Tumor Mutation Burden and Efficacy of EGFR-Tyrosine Kinase Inhibitors in Patients with EGFR-Mutant Lung Cancers
- (2018) Michael Offin et al. CLINICAL CANCER RESEARCH
- IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade
- (2017) Mark Ayers et al. JOURNAL OF CLINICAL INVESTIGATION
- Phase II Trial of Atezolizumab As First-Line or Subsequent Therapy for Patients With Programmed Death-Ligand 1–Selected Advanced Non–Small-Cell Lung Cancer (BIRCH)
- (2017) Solange Peters et al. JOURNAL OF CLINICAL ONCOLOGY
- Clinical Outcome of ALK -Positive Non–Small Cell Lung Cancer (NSCLC) Patients with De Novo EGFR or KRAS Co-Mutations Receiving Tyrosine Kinase Inhibitors (TKIs)
- (2017) Sabine Schmid et al. Journal of Thoracic Oncology
- Dabrafenib plus trametinib in patients with previously untreated BRAF V600E -mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial
- (2017) David Planchard et al. LANCET ONCOLOGY
- Inactivation of DNA repair triggers neoantigen generation and impairs tumour growth
- (2017) Giovanni Germano et al. NATURE
- Elements of cancer immunity and the cancer–immune set point
- (2017) Daniel S. Chen et al. NATURE
- First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion Study
- (2017) Ryan J. Sullivan et al. Cancer Discovery
- Prognostic value of KRAS mutation in advanced non-small-cell lung cancer treated with immune checkpoint inhibitors: A meta-analysis and review
- (2017) Jung Han Kim et al. Oncotarget
- JAK-STAT-mediated chronic inflammation impairs cytotoxic T lymphocyte activation to decrease anti-PD-1 immunotherapy efficacy in pancreatic cancer
- (2017) Chunwan Lu et al. OncoImmunology
- The role of the ALK receptor in cancer biology
- (2016) B. Hallberg et al. ANNALS OF ONCOLOGY
- Potential Predictive Value of TP53 and KRAS Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma
- (2016) Zhong-Yi Dong et al. CLINICAL CANCER RESEARCH
- EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer: A Retrospective Analysis
- (2016) J. F. Gainor et al. CLINICAL CANCER RESEARCH
- ROS1fusions in cancer: a review
- (2016) Arnaud Uguen et al. Future Oncology
- Clinical Significance of PD-L1 Protein Expression in Surgically Resected Primary Lung Adenocarcinoma
- (2016) Kazuki Takada et al. Journal of Thoracic Oncology
- Programmed Cell Death Ligand 1 Expression in Resected Lung Adenocarcinomas: Association with Immune Microenvironment
- (2016) Tiffany G. Huynh et al. Journal of Thoracic Oncology
- Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
- (2016) Martin Reck et al. NEW ENGLAND JOURNAL OF MEDICINE
- p53 in the DNA-Damage-Repair Process
- (2016) Ashley B. Williams et al. Cold Spring Harbor Perspectives in Medicine
- PD-L1 expression in non-small cell lung cancer: Correlations with genetic alterations
- (2016) Andreas H. Scheel et al. OncoImmunology
- Immune Checkpoint inhibitors: An introduction to the next-generation cancer immunotherapy
- (2015) Lucy Lee et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Clinicopathologic analysis of programmed cell death-1 and programmed cell death-ligand 1 and 2 expressions in pulmonary adenocarcinoma: comparison with histology and driver oncogenic alteration status
- (2015) Jaemoon Koh et al. MODERN PATHOLOGY
- Differential association of STK11 and TP53 with KRAS mutation-associated gene expression, proliferation and immune surveillance in lung adenocarcinoma
- (2015) M B Schabath et al. ONCOGENE
- Association of PD-L1 overexpression with activating EGFR mutations in surgically resected nonsmall-cell lung cancer
- (2014) K. Azuma et al. ANNALS OF ONCOLOGY
- PD-1 and PD-L1 expression in molecularly selected non-small-cell lung cancer patients
- (2014) A D'Incecco et al. BRITISH JOURNAL OF CANCER
- Programmed cell death-ligand 1 expression in surgically resected stage I pulmonary adenocarcinoma and its correlation with driver mutations and clinical outcomes
- (2014) Ching-Yao Yang et al. EUROPEAN JOURNAL OF CANCER
- Multicenter Immunohistochemical ALK-Testing of Non–Small-Cell Lung Cancer Shows High Concordance after Harmonization of Techniques and Interpretation Criteria
- (2014) Maximilian von Laffert et al. Journal of Thoracic Oncology
- Signatures of mutational processes in human cancer
- (2013) Ludmil B. Alexandrov et al. NATURE
- Non-Small Cell Lung Cancer: Epidemiology, Risk Factors, Treatment, and Survivorship
- (2012) Julian R. Molina et al. MAYO CLINIC PROCEEDINGS
- Cross-talk between myeloid-derived suppressor cells (MDSC), macrophages, and dendritic cells enhances tumor-induced immune suppression
- (2012) Suzanne Ostrand-Rosenberg et al. SEMINARS IN CANCER BIOLOGY
- A Critical Role for Macrophages in Promotion of Urethane-Induced Lung Carcinogenesis
- (2011) R. Zaynagetdinov et al. JOURNAL OF IMMUNOLOGY
- Frequency and Distinctive Spectrum of KRAS Mutations in Never Smokers with Lung Adenocarcinoma
- (2008) G. J. Riely et al. CLINICAL CANCER RESEARCH
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now